Brief: Elanco's Credelio Quattro™-Ca1 Receives First FDA Conditional Approval
18/12/2025 14:11
Dec 18 (Reuters) - Elanco Animal Health Inc ELAN.N: ELANCO'S CREDELIO QUATTRO™-CA1 (LOTILANER, MOXIDECTIN, PRAZIQUANTEL, AND PYRANTEL CHEWABLE TABLETS) RECEIVES FIRST FDA CONDITIONAL APPROVAL FOR TREATMENT OF NEW WORLD SCREWWORM IN DOGS Source text: ID:nPn7T5zQZa Further company coverage: ELAN.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elanco Animal Health Incorporated
See all newsBrief: Elanco Animal Health Appoints Jamie Preston As Chief People Officer
U.S. STOCKS ON THE MOVE-Walt Disney, Alphabet, Kraft Heinz
U.S. STOCKS ON THE MOVE-Wynn Resorts, Griffon, Kratos Defense, Amgen
Elanco Animal Health Incorporated reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cencora, Charles River, Twist Bioscience